navitoclax

Term ID

CHEBI:131174

Synonyms

• 4-{4-[(4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro[biphenyl]-2-yl)methyl]piperazin-1-yl}-N-[(4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]benzamide
• A-855071.0
• ABT 263
• ABT-263
• ABT263
• navitoclax
• navitoclaxum

Definition

A N-sulfonylcarboxamide resulting from the formal condensation of the carboxy group of 4-{4-[(4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro[biphenyl]-2-yl)methyl]piperazin-1-yl}benzoic acid with the amino group of 4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide. It is a BH3-mimetic drug which targets the anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, including BCL-2, BCL-xL, and BCL-w, and induces apoptosis in cancer cells. Currently under clinical investigation as treatment for solid tumors and hematologic malignancies.

References

• cas:923564-51-6
• chemspider:21864722
• drugbank:DB12340
• kegg.drug:D09935
• lincs.smallmolecule:LSM-42776
• lincs.smallmolecule:LSM-4738
• pdb-ccd:1XJ
• pmc:PMC6011937
• pubmed:18085673
• pubmed:23291630
• pubmed:26575826
• pubmed:26958630
• pubmed:28713162
• pubmed:28947240
• pubmed:29156797
• pubmed:29237758
• pubmed:29580266
• pubmed:29753379
• pubmed:29913235
• pubmed:30224339
• pubmed:30614795
• pubmed:30721730
• pubmed:30919222
• pubmed:31276572
• pubmed:31367332
• pubmed:31399555
• pubmed:31459977
• pubmed:32247610
• pubmed:32337074
• pubmed:32446890
• pubmed:32509782
• pubmed:32611834
• pubmed:32652830
• pubmed:32675749
• pubmed:32687646
• wikipedia.en:Navitoclax

Ontology

ChEBI  ( EBI )